RA Capital Management’s blank-check entity Research Alliance III raised $75 million in its IPO to merge into an existing biotechnology company. The SPAC sold 7.5 million shares at $10 each and began trading on Nasdaq under ticker “RACC,” with the stated intent to pursue a combination with a target spanning drug development, diagnostics, and healthcare technology and services. The filing described an execution-driven strategy, drawing on RA Capital’s prior experience with earlier blank-check vehicles: Research Alliance I merged into Point Biopharma in 2021, which Eli Lilly later acquired in 2023 for $1.4 billion. A second prior SPAC did not secure a partner and liquidated. Analysts have linked the renewed interest in SPAC structures to the slowdown in traditional biotech IPOs and the need for alternative paths to the public markets. The prospectus also indicated the market environment may improve the SPAC’s ability to locate an attractive target. For biotech companies considering liquidity options, the RA Capital SPAC indicates that capital markets are still exploring route-to-public strategies when conventional IPO windows remain narrow.